Damon Reed, MD

Memorial Sloan Kettering
New York, New York, United States

Disclosure information not submitted.

Presentation(s):

• Paper 24 - A PHASE IB STUDY TO EVALUATE THE FEASIBILITY OF NIVOLUMAB OR NIVOLUMAB WITH AZACITIDINE IN PATIENTS WITH RECURRENT, RESECTABLE OSTEOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

  Thursday, November 14, 2024
  1:45 PM – 3:15 PM PST

• Paper 45 - A PHASE II STUDY OF PALBOCICLIB COMBINED WITH THE PD-1 INHIBITOR RETIFANLIMAB IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Paper 71 - SECOND MALIGNANT NEOPLASM FOLLOWING TREATMENT FOR NON-METASTATIC EWING SARCOMA IN PATIENTS ENROLLED ON FRONTLINE PHASE 3 CLINICAL TRIALS: A REPORT FROM CHILDREN'S ONCOLOGY GROUP

  Saturday, November 16, 2024
  8:00 AM – 9:00 AM PST

• Paper 89 - PERIPHERAL BLOOD T CELL PHENOTYPE AND TUMOR MICROENVIRONMENT SUBTYPE ARE INDEPENDENTLY ASSOCIATED WITH IMMUNE CHECKPOINT BLOCKADE OUTCOMES IN SARCOMAS

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST